Table 2

Characteristics of patients with active disease at the time of sampling

Patient number

Age (years)

ANCA type

Disease duration (months)

Disease activity at time of sampling

BVAS

CRP (mg/L)

1

55

PR3

0

A, ENT, K, L

25

292

2

37

PR3

44

A, ENT

5

20

3

55

PR3

57

A, K, L

15

247

4

58

MPO

120

A, L

7

23

5

49

PR3

190

A, ENT, L

10

46

6

57

PR3

259

Ey, ENT

6

< 5

7

56

PR3

191

Ey

6

< 5

8

82

MPO

0

L

4

44

9

53

PR3

0

A, ENT, K, L

17

160

10

74

PR3

0

K

10

NA

11

69

PR3

9

ENT, K

14

211

12

41

MPO

0

A, ENT, K, S

17

44

13

58

MPO

0

ENT, K, S

14

116

14

70

MPO

0

A, ENT, K, L

19

188

15

53

PR3

15

Ey, K

12

12

16

24

PR3

9

A, Ey

3

16

17

40

MPO

33

ENT

6

< 5

18

41

MPO

284

K, L

12

< 5

None of the patients received induction therapy at the time of sampling. PR3/MPO, proteinase-3/myeloperoxidase; this reflects anti-neutrophil-cytoplasmic antibodies specificity (ANCA) at the time of diagnosis. Organ involvement of patients with active disease at the time of sampling is depicted. A, arthritis (joints); BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; ENT, ear-nose-throat; Ey, ophthalmologic manifestation of disease; K, kidney; L, lung; S, skin.

Wilde et al. Arthritis Research & Therapy 2012 14:R227   doi:10.1186/ar4066